Stukel Therese A, Lucas F Lee, Wennberg David E
Center for the Evaluative Clinical Sciences, Dartmouth Medical School, Hanover, NH, USA.
JAMA. 2005 Mar 16;293(11):1329-37. doi: 10.1001/jama.293.11.1329.
The health and policy implications of the marked regional variations in intensity of invasive compared with medical management of patients with acute myocardial infarction (AMI) are unknown.
To evaluate patient clinical characteristics associated with receiving more intensive treatment; and to assess whether AMI patients residing in regions with more intensive invasive treatment and management strategies have better long-term survival than those residing in regions with more intensive medical management strategies.
DESIGN, SETTING, AND PATIENTS: National cohort study of 158,831 elderly Medicare patients hospitalized with first episode of confirmed AMI in 1994-1995, followed up for 7 years (mean, 3.6 years), according to the intensity of invasive management (performance of cardiac catheterization within 30 days) and medical management (prescription of beta-blockers to appropriate patients at discharge) in their region of residence. Baseline chart reviews were drawn from the Cooperative Cardiovascular Project and linked to Medicare health administrative data.
Long-term survival over 7 years of follow-up.
Patient baseline AMI severity was similar across regions. In all regions, younger and healthier patients were more likely than older high-risk patients to receive invasive treatment and medical therapy. Regions with more invasive treatment practice styles had more cardiac catheterization laboratory capacity; patients in these regions were more likely to receive interventional treatment, regardless of age, clinical indication, or risk profile. The absolute unadjusted difference in 7-year survival between regions providing the highest rates of both invasive and medical management strategies and those providing the lowest rates of both was 6.2%. For both ST- and non-ST-segment elevation AMI patients, survival improved with regional intensity of both invasive and medical management. In areas with higher rates of medical management, there appeared to be little or no improvement in survival associated with increased invasive treatment.
In elderly Medicare patients with AMI, more intensive medical treatment provides population survival benefits. However, routine use of more costly and invasive treatment strategies may not be associated with an overall population benefit beyond that seen with excellent medical management. Efforts should focus on directing invasive clinical resources to patients with the greatest expected benefit.
与急性心肌梗死(AMI)患者的药物治疗相比,侵入性治疗强度的显著地区差异对健康和政策的影响尚不清楚。
评估与接受更强化治疗相关的患者临床特征;并评估居住在侵入性治疗和管理策略更强化地区的AMI患者是否比居住在药物管理策略更强化地区的患者具有更好的长期生存率。
设计、地点和患者:对1994 - 1995年因首次确诊AMI住院的158,831名老年医疗保险患者进行全国队列研究,根据其居住地区的侵入性管理强度(30天内进行心脏导管插入术)和药物管理强度(出院时对合适患者开具β受体阻滞剂处方)进行随访7年(平均3.6年)。基线病历审查来自合作心血管项目,并与医疗保险健康管理数据相关联。
7年随访期内的长期生存率。
各地区患者基线AMI严重程度相似。在所有地区,年轻且健康的患者比年老的高危患者更有可能接受侵入性治疗和药物治疗。侵入性治疗实践方式更多的地区心脏导管插入实验室能力更强;这些地区的患者更有可能接受介入治疗,无论年龄、临床指征或风险状况如何。提供侵入性和药物管理策略最高比率的地区与提供最低比率的地区之间,7年生存率的绝对未调整差异为6.2%。对于ST段和非ST段抬高的AMI患者,侵入性和药物管理的地区强度越高,生存率越高。在药物管理率较高的地区,侵入性治疗增加似乎对生存率几乎没有改善或没有改善。
在患有AMI的老年医疗保险患者中,更强化的药物治疗可带来总体人群生存益处。然而,常规使用成本更高且侵入性更强的治疗策略可能不会带来超出优秀药物管理的总体人群益处。应努力将侵入性临床资源导向预期获益最大的患者。